- Home
- CASI vs RLYB Comparison
CASI vs RLYB Comparison
Compare CASI & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CASI
- RLYB
- Stock Information
- Founded
- CASI 1991
- RLYB 2018
- Country
- CASI China
- RLYB United States
- Employees
- CASI N/A
- RLYB N/A
- Industry
- CASI Biotechnology: Pharmaceutical Preparations
- RLYB Biotechnology: Pharmaceutical Preparations
- Sector
- CASI Health Care
- RLYB Health Care
- Exchange
- CASI Nasdaq
- RLYB Nasdaq
- Market Cap
- CASI 24.9M
- RLYB 24.1M
- IPO Year
- CASI 1996
- RLYB 2021
- Fundamental
- Price
- CASI $1.30
- RLYB $0.64
- Analyst Decision
- CASI Strong Buy
- RLYB Hold
- Analyst Count
- CASI 1
- RLYB 2
- Target Price
- CASI $4.00
- RLYB N/A
- AVG Volume (30 Days)
- CASI 26.7K
- RLYB 263.4K
- Earning Date
- CASI 11-14-2025
- RLYB 11-06-2025
- Dividend Yield
- CASI N/A
- RLYB N/A
- EPS Growth
- CASI N/A
- RLYB N/A
- EPS
- CASI N/A
- RLYB N/A
- Revenue
- CASI $31,564,000.00
- RLYB $674,000.00
- Revenue This Year
- CASI N/A
- RLYB N/A
- Revenue Next Year
- CASI N/A
- RLYB N/A
- P/E Ratio
- CASI N/A
- RLYB N/A
- Revenue Growth
- CASI 36.64
- RLYB 12.71
- 52 Week Low
- CASI $1.09
- RLYB $0.22
- 52 Week High
- CASI $5.95
- RLYB $1.24
- Technical
- Relative Strength Index (RSI)
- CASI 35.39
- RLYB 53.76
- Support Level
- CASI $1.29
- RLYB $0.62
- Resistance Level
- CASI $1.48
- RLYB $0.72
- Average True Range (ATR)
- CASI 0.13
- RLYB 0.05
- MACD
- CASI -0.00
- RLYB 0.00
- Stochastic Oscillator
- CASI 0.00
- RLYB 37.50
About CASI CASI Pharmaceuticals Inc.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.